Your browser doesn't support javascript.
Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic.
Steinhardt, Laura C; Ige, Fehintola; Iriemenam, Nnaemeka C; Greby, Stacie M; Hamada, Yohhei; Uwandu, Mabel; Aniedobe, Maureen; Stafford, Kristen A; Abimiku, Alash'le; Mba, Nwando; Agala, Ndidi; Okunoye, Olumide; Mpamugo, Augustine; Swaminathan, Mahesh; Onokevbagbe, Edewede; Olaleye, Temitope; Odoh, Ifeanyichukwu; Marston, Barbara J; Okoye, McPaul; Abubakar, Ibrahim; Rangaka, Molebogeng X; Rogier, Eric; Audu, Rosemary.
  • Steinhardt LC; Malaria Branch, Division of Malaria and Parasitic Diseases, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Ige F; Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
  • Iriemenam NC; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Greby SM; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Hamada Y; Institute for Global Health, University College London, London, United Kingdom.
  • Uwandu M; Clinical Diagnostic Laboratory, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
  • Aniedobe M; Center for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
  • Stafford KA; Center for International Health, Education, and Biosecurity, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Abimiku A; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Mba N; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Agala N; International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.
  • Okunoye O; National Reference Laboratory, Nigeria Center for Disease Control, Abuja, Nigeria.
  • Mpamugo A; International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.
  • Swaminathan M; National Reference Laboratory, Nigeria Center for Disease Control, Abuja, Nigeria.
  • Onokevbagbe E; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Olaleye T; University of Maryland, Baltimore, Abuja, Nigeria.
  • Odoh I; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Marston BJ; University of Maryland, Baltimore, Abuja, Nigeria.
  • Okoye M; International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.
  • Abubakar I; International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.
  • Rangaka MX; Division of Malaria and Parasitic Diseases, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rogier E; Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Abuja, Nigeria.
  • Audu R; Institute for Global Health, University College London, London, United Kingdom.
J Clin Microbiol ; 59(7): e0051421, 2021 06 18.
Article in English | MEDLINE | ID: covidwho-1186207
Semantic information from SemMedBD (by NLM)
1. Measles Virus Nucleoprotein PART_OF 2019 novel coronavirus
Subject
Measles Virus Nucleoprotein
Predicate
PART_OF
Object
2019 novel coronavirus
2. Persons LOCATION_OF Plasma
Subject
Persons
Predicate
LOCATION_OF
Object
Plasma
3. abbott LOCATION_OF Assay
Subject
abbott
Predicate
LOCATION_OF
Object
Assay
4. 2019 novel coronavirus PROCESS_OF Patients
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Patients
5. Patients LOCATION_OF Antibodies
Subject
Patients
Predicate
LOCATION_OF
Object
Antibodies
6. Antibodies STIMULATES urea
Subject
Antibodies
Predicate
STIMULATES
Object
urea
7. Measles Virus Nucleoprotein PART_OF 2019 novel coronavirus
Subject
Measles Virus Nucleoprotein
Predicate
PART_OF
Object
2019 novel coronavirus
8. Persons LOCATION_OF Plasma
Subject
Persons
Predicate
LOCATION_OF
Object
Plasma
9. abbott LOCATION_OF Assay
Subject
abbott
Predicate
LOCATION_OF
Object
Assay
10. 2019 novel coronavirus PROCESS_OF Patients
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Patients
11. Patients LOCATION_OF Antibodies
Subject
Patients
Predicate
LOCATION_OF
Object
Antibodies
12. Antibodies STIMULATES urea
Subject
Antibodies
Predicate
STIMULATES
Object
urea
ABSTRACT
Accurate SARS-CoV-2 serological assays are critical for COVID-19 serosurveillance. However, previous studies have indicated possible cross-reactivity of these assays, including in areas where malaria is endemic. We tested 213 well-characterized prepandemic samples from Nigeria using two SARS-CoV-2 serological assays, Abbott Architect IgG and Euroimmun NCP IgG assay, both targeting SARS-CoV-2 nucleocapsid protein. To assess antibody binding strength, an avidity assay was performed on these samples and on plasma from SARS-CoV-2 PCR-positive persons. Thirteen (6.1%) of 212 samples run on the Abbott assay and 38 (17.8%) of 213 run on the Euroimmun assay were positive. Anti-Plasmodium IgG levels were significantly higher among false positives for both Abbott and Euroimmun; no association was found with active Plasmodium falciparum infection. An avidity assay using various concentrations of urea wash in the Euroimmun assay reduced loosely bound IgG of 37 positive/borderline prepandemic samples, 46%, 86%, 89%, and 97% became negative using 2 M, 4 M, 5 M, and 8 M urea washes, respectively. The wash slightly reduced avidity of antibodies from SARS-CoV-2 patients within 28 days of PCR confirmation; thereafter, avidity increased for all urea concentrations except 8 M. This validation found moderate to substantial cross-reactivity on two SARS-CoV-2 serological assays using samples from a setting where malaria is endemic. A simple urea wash appeared to alleviate issues of cross-reactivity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Malaria Type of study: Diagnostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Africa Language: English Journal: J Clin Microbiol Year: 2021 Document Type: Article Affiliation country: JCM.00514-21

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Malaria Type of study: Diagnostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Africa Language: English Journal: J Clin Microbiol Year: 2021 Document Type: Article Affiliation country: JCM.00514-21